PRECLINICAL AND CLINICAL STUDIES ON RU 28965

The authors investigated a new macrolide, RU 28965, preclinically and clinically. Results revealed that the transport of RU 28965 to lymph was good, particularly to the right truncus, thus indicating that transport to pulmonary tissue was good. Clinically, doses of 200-400mg of RU 28965 were orally...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement4; pp. 324 - 328
Main Authors TAKEDA, HIROAKI, MIURA, HIROSHI, KAWAHIRA, MASAHIDE, KOBAYASHI, HIROYUKI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1988
Online AccessGet full text

Cover

More Information
Summary:The authors investigated a new macrolide, RU 28965, preclinically and clinically. Results revealed that the transport of RU 28965 to lymph was good, particularly to the right truncus, thus indicating that transport to pulmonary tissue was good. Clinically, doses of 200-400mg of RU 28965 were orally administered to 12 patients with respiratory infections including 3 with acute bronchitis, 1 with pneumonitis, 4 with chronic bronchitis and 4 with bronchial asthma complicated by infection. RU 28965 was clinically effective in all 12 cases. Neither side-effects nor abnormal variations in the laboratory test results were observed. From the aforementioned results, we conclude that RU 28965 can be used safely in various respiratory infections ind reasonable effects can be expected.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.36.Supplement4_324